Nxera Pharma Co Ltd
Nxera Pharma's capital structure shows a debt-to-equity ratio of 0.94, indicating a moderate reliance on debt financing. The company holds JPY 20.37 billion in cash and equivalents, but this is offset by JPY 57.38 billion in long-term debt, resulting in a net cash position of negative JPY 37.01 billion. The liquidity risk is rated as medium, with a current ratio of 2.54, suggesting the company has sufficient short-term assets to cover its liabilities, but its operating cash flow of negative JPY 2.67 billion indicates ongoing cash burn. Profitability metrics are weak, with a return on equity of -20.54% and a return on assets of -9.3%, both significantly below industry norms for pharmaceutical firms. The company reported an operating loss of JPY 8.46 billion and a net loss of JPY 12.53 billion in the latest period, reflecting challenges in achieving profitability despite a gross profit of JPY 21.42 billion. Nxera Pharma's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of segment or geographic diversification increases exposure to market-specific risks, particularly in Japan, where the company is headquartered. The company's growth trajectory is uncertain, with no specific revenue growth rates provided in the input data. However, the negative operating and net income suggest that the company is not currently generating sustainable earnings. The absence of positive cash flow from operations further complicates its ability to fund growth internally. Risk factors include a high debt load and negative cash flow, which could lead to liquidity constraints. The risk assessment indicates a low probability of dilution, but the company's negative net cash position and operating losses suggest potential for future equity issuance to fund operations or debt obligations. Recent events include the publication of the latest financial results, which show continued losses and a negative cash flow. No specific recent filings or transcripts are provided in the input data, so the narrative is based on the most recent financial snapshot.
Business. Nxera Pharma Co Ltd is a Japanese pharmaceutical company that develops and commercializes prescription drugs, primarily in the oncology and rare disease therapeutic areas.
Classification. Nxera Pharma is classified under the Pharmaceuticals industry within the Healthcare economic sector, with a high confidence level of 0.92 based on verified market data.
- Nxera Pharma is operating at a loss with a negative return on equity and assets.
- The company has a high debt load and negative net cash position, increasing liquidity risk.
- Profitability is weak, with no clear path to positive earnings in the near term.
- The company lacks geographic and segment diversification, increasing exposure to market-specific risks.
- Analysts are divided on the stock, with a mean price target of JPY 1,988 and a median of JPY 1,100.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.